secwatch.observer — SEC 8-K summary
======================================

Issuer:     PLUS THERAPEUTICS, INC. (PSTV)
CIK:        0001095981
Form:       8-K
Filed at:   2023-11-20T23:59:59+00:00
Accession:  0001193125-23-280212
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Plus Therapeutics Phase 2 GBM trial: mOS 13 mo (63% above SOC), mPFS 11 mo
--------------------------------------------------------------------------

- Median overall survival 13 months in 15 rGBM patients, 63% better than SOC bevacizumab (8 mo).
- Median progression-free survival 11 months vs SOC 4 months; 9 of 15 patients remain alive.
- Delivers up to 20x radiation dose (740 Gy) vs EBRT (35 Gy); favorable safety profile maintained.
- Imaging analysis confirms efficacy signal; company to host KOL webinar Nov 20 at 10 am ET.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1095981/000119312523280212/0001193125-23-280212-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1095981/000119312523280212/d620464d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-280212

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer